ERBB2 and gastric cancer: For HER2‐negative advanced or metastatic gastric cancer, the phase III KEYNOTE‐859 trial evaluated pembrolizumab plus chemotherapy (fluorouracil with cisplatin or capecitabine with oxaliplatin) versus placebo plus chemotherapy in the first‐line setting.